Bingrui Li, Ph.D.
Department of Cancer Biology, Division of Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Cancer Biology, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2023 | The University of Texas Health Science Center Houston, Houston, Texas, US, Biomedical Informatics, Ph.D |
Postgraduate Training
| 2023-2025 | Postdoctoral Fellow, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Administrative Appointments/Responsibilities
President, Chinese Student & Scholar Association at UTHealth, Houston, Texas, 2022 - 2023
Class Monitor, Department of BGI-QDU Innovation College, Qingdao University, Qingdao, Shandong, 2014 - 2018
Other Professional Positions
Bioinformatics Engineer, Bioinformatics and Machine Learning, Deep Intelligent Pharma Inc, Beijing, Beijing, 2018 - 2018
Undergraduate Research Assistant, Bioinformatics and Computational Biology, BGI, Shenzhen, Guangdong, 2017 - 2018
Editorial Activities
Guest Editor, Biomedicines, 2024 - Present
Review Editor, Frontiers in Big Data, 2024 - Present
Review Editor, Frontiers in Artificial Intelligence, 2024 - Present
Honors & Awards
| 2024 - Present | MIT Policy Hackathon, MIT |
| 2016 | Third Prize of National College Students Preclinical Medicine Innovation Competition, The National Experimental Teaching Demonstration Centers in Higher Education (China) |
Selected Presentations & Talks
National Presentations
- 2022. Machine Learning Identifies Exosome Protein Signatures to Distinguish Multiple Human Cancers. Poster. AAEV/ASEMV Conference 2022. Pacific Grove, California, US.
Selected Publications
Peer-Reviewed Articles
- Li B, Zhou X, Kalluri R. scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing. Adv. Sci, 2025. e-Pub 2025.
- Zhou X, LeBleu VS, Fletcher-Sananikone E, Kim J, Dai J, Li B, Wu C, Sugimoto H, Miyake T, Becker LM, Volpert OV, Lawson E, Da Silva CE, Patel SI, Kizu A, Ehsanipour EA, Sha D, Karam JA, McAndrews KM, Kalluri R. Vascular heterogeneity of tight junction Claudins guides organotropic metastasis. Nat Cancer:1-19, 2024. e-Pub 2024.
- Mahadevan KK, Dyevoich AM, Chen Y, Li B, Sugimoto H, Sockwell AM, McAndrews KM, Sthanam LK, Wang H, Shalapour S, Watowich SS, Kalluri R. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Science 384(6703):eadh4567, 2024. e-Pub 2024.
- Li B, Kugeratski FG, Kalluri R. A novel machine learning algorithm selects proteome signature to specifically identify cancer exosomes. Elife 12:RP90390, 2024. e-Pub 2024.
- Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, Sockwell AM, Kirtley ML, Morse SJ, Moreno Diaz BA, Kim MP, Feng N, Lopez AM, Guerrero PA, Paradiso F, Sugimoto H, Arian KA, Ying H, Barekatain Y, Sthanam LK, Kelly PJ, Maitra A, Heffernan TP, Kalluri R. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell 41(9):1606-1620. e8, 2023. e-Pub 2023.
- Haltom AR, Hassen WE, Hensel J, Kim J, Sugimoto H, Li B, McAndrews KM, Conner MR, Kirtley ML, Luo X, Xie B, Volpert OV, Olalekan S, Maltsev N, Basu A, LeBleu VS, Kalluri R. Engineered exosomes targeting MYC reverse the proneural-mesenchymal transition and extend survival of glioblastoma. Extracellular vesicle 1:100014, 2022. e-Pub 2022.
- Dai Y, Yu H, Yan Q, Li B, Liu A, Liu W, Jiang X, Kim Y, Guo Y, Zhao Z. Drug-Target Network Study Reveals the Core Target-Protein Interactions of Various COVID-19 Treatments. Genes (Basel) 13(7):1210, 2022. e-Pub 2022.
- McAndrews KM, Chen Y, Darpolor J, Zheng X, Yang S, Carstens JL, Li B, Wang H, Miyake T, de Sampaio PC, Kirtley ML, Natale M, Wu C, Sugimoto H, LeBleu VS, Kalluri R. Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer. Cancer discovery 12(6):1580-1597, 2022. e-Pub 2022.
- Li B, Lu X, McAndrews KM, Kalluri R. Mutations in the spike RBD of SARS-CoV-2 omicron variant may increase infectivity without dramatically altering the efficacy of current multi-dosage vaccinations. bioRxiv:2021.12. 08.471688. e-Pub 2021.
- Mahadevan KK, LeBleu VS, Ramirez EV, Chen Y, Li B, Sockwell AM, Gagea M, Sugimoto H, Sthanam LK, Tampe D, Zeisberg M, Ying H, Jain AK, DePinho RA, Maitra A, McAndrews KM, Kalluri R. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Dev Cell 58(17):1562-1577. e8, 2021. e-Pub 2021.
- Li B, Pei G, Yao J, Ding Q, Jia P, Zhao Z. Cell-type deconvolution analysis identifies cancer-associated myofibroblast component as a poor prognostic factor in multiple cancer types. Oncogene 40(28):4686-4694, 2021. e-Pub 2021.
- McAndrews KM, Vázquez-Arreguín K, Kwak C, Sugimoto H, Zheng X, Li B, Kirtley ML, LeBleu VS, Kalluri R. αSMA+ fibroblasts suppress Lgr5+ cancer stem cells and restrain colorectal cancer progression. Oncogene 40(26):4440-4452, 2021. e-Pub 2021.
- Zhou X, Xiao F, Sugimoto H, Li B, McAndrews KM, Kalluri R. Acute Kidney Injury Instigates Malignant Renal Cell Carcinoma via CXCR2 in Mice with Inactivated Trp53 and Pten in Proximal Tubular Kidney Epithelial Cells. Cancer Res 81(10):2690-2702, 2021. e-Pub 2021.
- Tang M, Chen Y, Li B, Sugimoto H, Yang S, Yang C, LeBleu VS, McAndrews KM, Kalluri R. Therapeutic targeting of STAT3 employing small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis. FASEB J 35(5):e21557, 2021. e-Pub 2021.
- Tang D, Li B, Xu T, Hu R, Tan D, Song X, Jia P, Zhao Z. VISDB: a manually curated database of viral integration sites in the human genome. Nucleic Acids Res 48(D1):D633-D641, 2021. e-Pub 2021.
- Li B, Dai C, Wang L, Deng H, Li Y, Guan Z, Ni H. A novel drug repurposing approach for non-small cell lung cancer using deep learning. PLoS One 15(6):e0233112, 2020. e-Pub 2020.
- McAndrews KM, Hensel J, Xiao F, Li B, LeBleu VS, Kalluri R. MYC regulates pancreatic cancer initiation through reprogramming of carcinoma-associated fibroblasts and tumor immunity. In submission process.
- McAndrews KM, Kim J, Haltom AR, Kelly PJ, Moreno Diaz BA, BA, Li B, Hensel J, Ruivo CF, Kalluri R. Early transfer of cancer cell derived CD9+ extracellular vesicles reprograms the pancreatic tumor microenvironment. In submission process.
- McAndrews KM, Mahadevan KK, Li B, Sockwell AM, Morse SJ, Kelly PJ, Kirtley ML, Conner MR, Patel SI, Khumbar SV, Arian KA, Barekatain Y, Moreno Diaz BA, Lyu H, Sugimoto H, Sthanam LK, Sobhani N, Paradiso F, Bernard V, Guerrero P, Ying H, Maitra A, Heffernan TP, Kalluri R. CDK8 remodels the tumor microenvironment to contribute to KRASG12D small molecule inhibitor resistance in pancreatic ductal adenocarcinoma. Under revision.
Other Articles
- Li B, Hu Y, Kalluri R Human extracellular vesicle blueprints: Extracellular vesicles. Nat Cell Biol, 2025.
Patient Reviews
CV information above last modified January 20, 2026